安大略省八旬和九旬炎症性肠病患者生物治疗的安全性：病例系列 - Suppr

Suppr

超能文献

Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.

作者信息

Ayoub Abdul, Jairath Vipul, Aldraiweesh Saleh, Khanna Reena, Gregor Jamie, Chande Nilesh

机构信息

Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.

Robarts Clinical Trials, London, Ontario, Canada.

出版信息

Inflamm Bowel Dis. 2020 Nov 19;26(12):e157-e158. doi: 10.1093/ibd/izaa182.

DOI:10.1093/ibd/izaa182

PMID:32651999

Abstract

摘要

相似文献

Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.

Inflamm Bowel Dis. 2020 Nov 19;26(12):e157-e158. doi: 10.1093/ibd/izaa182.

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.

Dig Dis Sci. 2019 Mar;64(3):855-862. doi: 10.1007/s10620-018-5319-6. Epub 2018 Oct 11.

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11.

Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile.

Curr Drug Saf. 2016;11(1):55-61. doi: 10.2174/157488631101160212171757.

Immunosuppression in inflammatory bowel disease: traditional, biological or both?

Curr Opin Gastroenterol. 2009 Jul;25(4):323-8. doi: 10.1097/MOG.0b013e32832c073a.

Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.

Dig Dis Sci. 2020 May;65(5):1436-1444. doi: 10.1007/s10620-019-05867-1. Epub 2019 Nov 1.

The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.

J Med Econ. 2020 Oct;23(10):1102-1110. doi: 10.1080/13696998.2020.1791889. Epub 2020 Jul 23.

The role of biologics in the treatment of patients with inflammatory bowel disease.

Br J Hosp Med (Lond). 2018 Dec 2;79(12):686-693. doi: 10.12968/hmed.2018.79.12.686.

Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x.

The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.

Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108. doi: 10.1080/17474124.2018.1530983. Epub 2018 Oct 10.

引用本文的文献

Orphan patients with inflammatory bowel disease - when we treat beyond evidence.

World J Gastroenterol. 2021 Dec 21;27(47):8047-8057. doi: 10.3748/wjg.v27.i47.8047.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.

作者信息

Ayoub Abdul, Jairath Vipul, Aldraiweesh Saleh, Khanna Reena, Gregor Jamie, Chande Nilesh

机构信息

Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.

Robarts Clinical Trials, London, Ontario, Canada.

出版信息

Inflamm Bowel Dis. 2020 Nov 19;26(12):e157-e158. doi: 10.1093/ibd/izaa182.

DOI:10.1093/ibd/izaa182

PMID:32651999

Abstract

摘要

相似文献

Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.

Inflamm Bowel Dis. 2020 Nov 19;26(12):e157-e158. doi: 10.1093/ibd/izaa182.

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.

Dig Dis Sci. 2019 Mar;64(3):855-862. doi: 10.1007/s10620-018-5319-6. Epub 2018 Oct 11.

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11.

Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile.

Curr Drug Saf. 2016;11(1):55-61. doi: 10.2174/157488631101160212171757.

Immunosuppression in inflammatory bowel disease: traditional, biological or both?

Curr Opin Gastroenterol. 2009 Jul;25(4):323-8. doi: 10.1097/MOG.0b013e32832c073a.

Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.

Dig Dis Sci. 2020 May;65(5):1436-1444. doi: 10.1007/s10620-019-05867-1. Epub 2019 Nov 1.

J Med Econ. 2020 Oct;23(10):1102-1110. doi: 10.1080/13696998.2020.1791889. Epub 2020 Jul 23.

The role of biologics in the treatment of patients with inflammatory bowel disease.

Br J Hosp Med (Lond). 2018 Dec 2;79(12):686-693. doi: 10.12968/hmed.2018.79.12.686.

Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x.

The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.

Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108. doi: 10.1080/17474124.2018.1530983. Epub 2018 Oct 10.

引用本文的文献

Orphan patients with inflammatory bowel disease - when we treat beyond evidence.

World J Gastroenterol. 2021 Dec 21;27(47):8047-8057. doi: 10.3748/wjg.v27.i47.8047.